Cover Image
Market Research Report

Global Ophthalmic Drugs Market Forecast 2019-2029: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs

Published by Visiongain Ltd Product code 239210
Published Content info 298 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Ophthalmic Drugs Market Forecast 2019-2029: Dry Eye, Glaucoma Drugs, Retinal Disorders Drugs and Allergic, Inflammatory & Infective Drugs
Published: June 17, 2019 Content info: 298 Pages
Description

The global ophthalmic drugs market is expected to grow at a CAGR of 4.8% in the first half of the forecast period. The market is estimated at $25bn in 2018, dominated by the retinal disorder drugs segment.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 298-page report you will receive 138 tables and 125 figures- all unavailable elsewhere.

The 298-page report provides clear detailed insight into the global ophthalmic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Ophthalmic Drugs market forecasts from 2019-2029
  • This report also breaks down the revenue forecasts to 2029 for the global ophthalmic drugs market by the leading submarkets:
  • Retinal Disorder Drugs
  • Allergic, Inflammatory & Infective Drugs
  • Glaucoma Drugs
  • Dry Eye Drugs
  • Other Ophthalmic Drugs
  • This report includes revenue forecasts to 2029 for the following ophthalmic drugs:
  • Eylea
  • Lucentis
  • Avastin
  • Visudyne
  • Jetrea
  • Pataday
  • Vigamox
  • Patanol
  • TobraDex
  • Cravit
  • AzaSite
  • Acular
  • Lumigan and Ganfort
  • Xalatan/Xalacom
  • Travatan/Travatan Z and DuoTrav
  • Alphagan/Alphagan P and Combigan
  • Azopt
  • Trusopt
  • Zioptan
  • Cosopt
  • Tapros/Taflotan
  • Restasis
  • Refresh
  • Hyalein
  • Diquas
  • This report provides individual revenue forecasts to 2029 for these national markets:
  • The US
  • Japan
  • EU5: Germany, France, the UK, Spain, Italy
  • Russia
  • China
  • India
  • Brazil
  • Rest of the World

Each national market is further segmented by the leading submarket: Retinal Disorder Drugs, Allergic, Inflammatory & Infective Drugs, Glaucoma Drugs, Dry Eye Drugs, Other Ophthalmic Drugs

Our study provides a SWOT analysis and discusses Porter's Five Forces analysis that influence the global ophthalmic drugs market

Our report provides discussion on the ophthalmic drugs that are currently in the development pipeline

  • Our study discusses the selected leading companies that are the major players in the ophthalmic drugs industry:
  • Allergan (Actavis)
  • Bayer
  • Novartis
  • Pfizer
  • Regeneron
  • Roche
  • Santen
  • Senju
  • Valeant

image1

  • Key Questions Answered by this Analysis:
  • How is the market for ophthalmic drugs evolving?
  • What is driving and restraining the ophthalmic drugs market dynamics?
  • What are the market shares of the submarkets for glaucoma drugs, allergic, inflammatory and infective drugs, dry eye drugs and retinal disorder drugs from the overall ophthalmic Drugs Market in 2018?
  • How will each of the submarket segments within the ophthalmic drugs market grow over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for each of the submarkets within the ophthalmic drugs market develop from 2018 to 2029?
  • Which submarkets will be the main driver of growth in the overall market from 2018 to 2029?
  • How will political, economic, and regulatory factors influence the regional markets and submarkets?
  • Will the leading regional markets for ophthalmic drugs broadly follow pre-existing trends, or will individual regions outperform the rest of the market?
  • How will the regional market shares in the ophthalmic drugs market change by 2029 and which geographical region will lead the market in 2029?
  • What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants?
  • How will the industry sector evolve as cost and pricing pressures increase during the period between 2018 and 2029?
Table of Contents
Product Code: PHA0439

Table of Contents

1. Report Overview

  • 1.1 Global Ophthalmic Drugs: Market Overview
  • 1.2 Global Ophthalmic Drugs Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who Is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. An Introduction to Ophthalmic Drugs

  • 2.1 The Pharmaceutical Industry: A Brief Introduction
    • 2.1.1 Ophthalmic Treatments - An Industry Overview
  • 2.2 The Human Eyes - Structurally Delicate and Functionally Intricate Organs
  • 2.3 The Global Burden of Eye Disease
  • 2.4 Ophthalmic Drugs: Market Segmentation
  • 2.5 Glaucoma: A Major Cause of Vision Loss
    • 2.5.1 A Classification of Glaucoma
      • 2.5.1.1 Primary Open-Angle Glaucoma
      • 2.5.1.2 Acute Angle-Closure Glaucoma
      • 2.5.1.3 Congenital Glaucoma
      • 2.5.1.4 Secondary Glaucoma
      • 2.5.1.5 Normal-Tension Glaucoma
      • 2.5.1.6 Ocular Hypertension
    • 2.5.2 Risk Factors for Glaucoma
    • 2.5.3 Diagnosis of Glaucoma
    • 2.5.4 Drug Treatment of Glaucoma
    • 2.5.5 Laser Treatment and Surgery for Glaucoma
  • 2.6 Age-Related Macular Degeneration (AMD)
    • 2.6.1 Dry (non-exudative) AMD
    • 2.6.2 Wet (exudative) AMD
    • 2.6.3 Risk Factors for AMD
    • 2.6.4 Diagnosis of AMD
    • 2.6.5 Treatment of AMD
  • 2.7 Diabetic Retinopathy (DR)
    • 2.7.1 Diagnosis of Diabetic Retinopathy
    • 2.7.2 Risk factor of Diabetic Retinopathy
    • 2.7.3 Treatment of Diabetic Retinopathy
  • 2.8 Ocular Allergy and Allergic Conjunctivitis
    • 2.8.1 Diagnosis of Ocular Allergy
    • 2.8.2 Treatment of Ocular Allergy
  • 2.9 Ocular Inflammatory Disease
    • 2.9.1 Risk factors of Ocular Inflammatory Disease
    • 2.9.2 Treatment of Ocular Inflammatory Disease
  • 2.10 Eye Infections
    • 2.10.1 Treatment of Eye Infections
  • 2.11 Dry Eye Syndrome
    • 2.11.1 Treatment of Dry Eye Syndrome
  • 2.12 Phases of Clinical Trials
  • 2.13 Ophthalmic Drugs: Market Definition in This Report

3. The Global Ophthalmic Drugs Market, 2019-2029

  • 3.1 The Global Ophthalmic Drugs Market: Market Overview
  • 3.2 Categorisation of the Global Ophthalmic Drugs Market
  • 3.3 The Global Ophthalmic Drugs Market In 2018
  • 3.4 The Global Ophthalmic Drugs Market: Market Forecast 2018-2029
  • 3.5 Ophthalmic Drugs: Changing Market Shares by Sector 2019-2029

4. The Retinal Disorder Drugs Market: Market Analysis and Forecast 2019-2029

  • 4.1 Leading Products in the Retinal Disorder Drugs Market, 2018
  • 4.2 Retinal Disorders: Market Trends and Developments, 2018
    • 4.2.1 The Rise of Eylea
    • 4.2.2 The Debate Around Off-Label Avastin Use and The Role of Novartis And Roche
    • 4.2.3 How Likely Is Avastin's Expansion into Age-Related Macular Degeneration?
    • 4.2.4 Jetrea: Underwhelming Sales Cause ThromboGenics to Switch Focus to Their Pipeline
    • 4.2.5 Drug/Device Combination Products Entering the Market
    • 4.2.6 Does Regenerative Medicine Have a Successful Future in Ophthalmics?
  • 4.3 Retinal Disorder Drugs: Market Forecast 2019-2029
    • 4.3.1 Retinal Disorder Drugs: Changing Market Shares by Leading Drugs 2019-2029
  • 4.4 Leading Drugs for The Treatment of Retinal Disorders
  • 4.5 Eylea (aflibercept) - Regeneron/ Bayer/ Santen
    • 4.5.1 Recent Approvals for Eylea
    • 4.5.2 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
    • 4.5.3 Eylea: Sales Forecast 2019-2029
    • 4.5.4 Possible Combination Therapies Involving Eylea
  • 4.6 Lucentis (ranibizumab) - Roche/ Novartis
    • 4.6.1 Lucentis: Sales Forecast 2019-2029
    • 4.6.2 Less Frequent Dosing Approved in US for Lucentis
    • 4.6.3 New Indications for Lucentis
    • 4.6.4 Possible Combination Therapy Involving Lucentis
  • 4.7 Avastin (bevacizumab) - Roche
    • 4.7.1 Avastin: Sales Forecast 2019-2029
    • 4.7.2 Compounding Pharmacies and Safety Risks
  • 4.8 Visudyne (verteporfin) - Valeant/ Novartis
    • 4.8.1 Visudyne: Sales Forecast 2019-2029
  • 4.9 Jetrea (ocriplasmin) - ThromboGenics/ Novartis
    • 4.9.1 Jetrea: Recent Sales Performance
    • 4.9.2 Clinical Study Plans for Jetrea
    • 4.9.3 Jetrea: Sales Forecast 2019-2029
    • 4.9.4 Possible Acquisition Move on ThromboGenics
    • 4.9.5 R&D Agreements with Eleven Biotherapeutics and Bicycle Therapeutics
  • 4.10 Other Retinal Disorder Drugs
    • 4.10.1 Iluvien (fluocinolone implant) - Alimera Sciences
    • 4.10.2 Ozurdex (dexamethasone implant) - Allergan
    • 4.10.3 Other Retinal Disorder Drugs: Sales Forecast 2018-2029

5. Allergic, Inflammatory & Infective Drugs Market: Market Analysis and Forecast 2019-2029

  • 5.1 Leading Products in The Allergic, Inflammatory and Infective Drugs Market, 2018
  • 5.2 Allergic, Inflammatory and Infective Drugs: Market Trends and Developments, 2018
    • 5.2.1 The Growth Prospects for Allergic, Inflammatory and Infective Drugs
    • 5.2.2 Topical NSAIDs Launched: Prolensa and Ilevro
  • 5.3 Allergic, Inflammatory and Infective Drugs: Market Forecast 2019-2029
    • 5.3.1 Allergic, Inflammatory and Infective Drugs: Changing Market Shares by Leading Drugs 2019-2029
  • 5.4 Leading Drugs for The Treatment of Allergic, Inflammatory and Infective Ophthalmic Conditions
  • 5.5 Patanol And Pataday (olopatadine) - Alcon (Novartis)
    • 5.5.1 Pataday: Sales Forecast 2018-2029
    • 5.5.2 Impending Generic Competition for Patanol And Pataday
    • 5.5.3 Approval of Pazeo Solution
    • 5.5.4 Patanol: Sales Forecast 2019-2029
  • 5.6 Vigamox (moxifloxacin) - Alcon (Novartis)
    • 5.6.1 Intensifying Competition and Generics Drug Challenge to Vigamox
    • 5.6.2 Moxeza: A Next-Generation Form of Vigamox
    • 5.6.3 Vigamox: Sales Forecast 2019-2029
  • 5.7 TobraDex (tobramycin/dexamethasone) - Alcon (Novartis)
    • 5.7.1 The Development and Commercialisation of TobraDex ST
    • 5.7.2 TobraDex: Sales Forecast 2019-2029
  • 5.8 Cravit (levofloxacin) - Santen
    • 5.8.1 Cravit: Sales Forecast 2019-2029
  • 5.9 Acular (ketorolac) - Allergan (Actavis)
    • 5.9.1 Acular: Sales Forecast 2019-2029
  • 5.10 AzaSite (azithromycin) - Akorn
    • 5.10.1 AzaSite: Sales Forecast 2019-2029
  • 5.11 Other Allergic, Inflammatory, and Infective Drugs: Sales Forecast 2019-2029

6. Glaucoma Drugs Market: Market Analysis and Forecast 2019-2029

  • 6.1 Glaucoma Drugs: Market Overview
    • 6.1.1 Leading Products in The Glaucoma Drugs Market, 2018
  • 6.2 Glaucoma Drugs: Market Trends and Developments, 2018
    • 6.2.1 Patent Expiration: A Major Restraint for Glaucoma Drugs
    • 6.2.2 Preservative-Free Formulation Trends
    • 6.2.3 Innovation in Treatments for Glaucoma
  • 6.3 Simbrinza: First Beta-Blocker-Free Combination
  • 6.4 Glaucoma Drugs: Market Forecast 2019-2029
    • 6.4.1 Glaucoma Drugs: Changing Market Shares by Leading Drugs 2019-2029
  • 6.5 Leading Drugs for The Treatment of Glaucoma
  • 6.6 Lumigan And Ganfort (bimatoprost) - Allergan (Actavis)
    • 6.6.1 Lumigan And Ganfort: Sales Forecast 2018-2029
  • 6.7 Xalatan And Xalacom (latanoprost) - Pfizer
    • 6.7.1 Xalatan/Xalacom: Sales Forecast 2019-2029
  • 6.8 Travatan/Travatan Z and DuoTrav (travoprost) - Novartis
    • 6.8.1 Travatan/Travatan Z and DuoTrav: Sales Forecast 2019-2029
  • 6.9 Alphagan/Alphagan P and Combigan (brimonidine) - Allergan
    • 6.9.1 Alphagan/Alphagan P and Combigan: Sales Forecast 2019-2029
  • 6.10 Trusopt And Cosopt/Cosopt PF (dorzolamide) - Merck/ Santen
    • 6.10.1 Divestment Agreement with Santen And Akorn
    • 6.10.2 Trusopt: Sales Forecast 2019-2029
    • 6.10.3 Cosopt And Cosopt PF: Sales Forecast 2019-2029
  • 6.11 Azopt (brinzolamide) - Novartis
    • 6.11.1 Azopt: Sales Forecast 2019-2029
  • 6.12 Tapros (tafluprost) - Santen
    • 6.12.1 Tapros: Sales Forecast 2019-2029
  • 6.13 Zioptan (tafluprost) - Akorn
    • 6.13.1 Zioptan: Sales Forecast 2019-2029
  • 6.14 Other Glaucoma Drugs: Sales Forecast 2019-2029

7. Dry Eye Drugs Market: Market Analysis and Forecast 2019-2029

  • 7.1 Dry Eye Drugs: Market Overview
    • 7.1.1 Leading Products in The Dry Eye Drugs Market, 2018
  • 7.2 Dry Eye Drugs: Market Trends and Developments, 2018
    • 7.2.1 Restasis: Patent Elongations and Generic Challenges Creating Uncertainty
    • 7.2.2 Intensifying Research Focused on Dry Eye
    • 7.2.3 Improving Diagnostic Tools
  • 7.3 Dry Eye Drugs: Market Forecast 2019-2029
    • 7.3.1 Dry Eye Drugs: Changing Market Shares by Leading Drugs 2019-2029
  • 7.4 Leading Drugs for The Treatment of Dry Eye
  • 7.5 Restasis (ciclosporin) - Allergan (Actavis)
    • 7.5.1 Restasis - Generic launch in 2016?
    • 7.5.2 Restasis: Sales Forecast 2019-2029
  • 7.6 Refresh Brand Products - Allergan (Actavis)
    • 7.6.1 Refresh Brand Products: Sales Forecast 2019-2029
  • 7.7 Hyalein (hyaluronic acid) - Santen
    • 7.7.1 Hyalein: Sales Forecast 2019-2029
  • 7.8 Diquas (diaquafosol) - Santen
    • 7.8.1 Diquas: Sales Forecast 2019-2029
  • 7.9 Other Dry Eye Drugs: Sales Forecast 2019-2029
  • 7.10 Other Ophthalmic Drugs
    • 7.10.1 Hetlioz (tasimelteon) - Vanda Pharmaceuticals
    • 7.10.2 Hetlioz: Sales Forecast 2019-2029

8. Leading National Markets for Ophthalmic Drugs, 2019-2029

  • 8.1 The Ophthalmic Drugs Market by Region
    • 8.1.1 The Global Distribution of Ophthalmic Drugs In 2018
  • 8.2 Leading National Markets: Forecast 2019-2029
    • 8.2.1 Changing Market Shares by Region, 2019-2029
  • 8.3 Regional Ophthalmic Drugs Markets: Analysis and Forecasts, 2019-2029
  • 8.4 United States: The Largest Ophthalmic Drugs Market
    • 8.4.1 How Will the Rise of a Biosimilars Market Impact on US Ophthalmic Drugs?
    • 8.4.2 US Ophthalmic Drugs Market: Market Forecast 2018-2029
  • 8.5 EU5
    • 8.5.1 EU5 Ophthalmic Drugs Market: Market Forecast 2018-2029
      • 8.5.1.1 EU5 Markets: Changing Market Shares by Country, 2019-2029
    • 8.5.2 Germany
      • 8.5.2.1 German Ophthalmic Drugs Market: Market Forecast 2019-2029
    • 8.5.3 France
      • 8.5.3.1 French Ophthalmic Drugs Market: Market Forecast 2019-2029
    • 8.5.4 UK
      • 8.5.4.1 UK Ophthalmic Drugs Market: Market Forecast 2019-2029
      • 8.5.4.2 Brexit - Increased Uncertainty May Affect the UK Ophthalmic Drug Market
    • 8.5.5 Italy
      • 8.5.5.1 Italian Ophthalmic Drugs Market: Market Forecast 2019-2029
    • 8.5.6 Spain
      • 8.5.6.1 Spanish Ophthalmic Drugs Market: Market Forecast 2019-2029
  • 8.6 Japan
    • 8.6.1 The Cost of Treatment in Japan
    • 8.6.2 Japanese Pharmaceutical Industry Regulatory Reform
    • 8.6.3 Japanese Ophthalmic Drugs Market Forecast 2019-2029
  • 8.7 China
    • 8.7.1 Expansion of Healthcare Coverage and Reimbursement in China
    • 8.7.2 Price Controls and The Anhui Model
    • 8.7.3 Chinese Ophthalmic Drugs Market: Market Forecast 2019-2029
  • 8.8 Brazil
    • 8.8.1 How Will Brazil's Growing Healthcare Influence Ophthalmic Drugs
    • 8.8.2 Brazilian Ophthalmic Drugs Market: Market Forecast 2019-2029
  • 8.9 Russia
    • 8.9.1 How Will Russia's Economic Status Affect Its Pharma Industry?
    • 8.9.2 Russian Ophthalmic Drugs Market: Market Forecast 2019-2029
  • 8.10 India
    • 8.10.1 The Impact of The Drug Prices Control Order on Indian Pharma
    • 8.10.2 India's Expansion of Healthcare Provision
    • 8.10.3 Indian Ophthalmic Drugs Market: Market Forecast 2019-2029
  • 8.11 Rest of the World
    • 8.11.1 Rest of the World Ophthalmic Drugs Market: Market Forecast 2019-2029

9. Leading Companies in the Ophthalmic Drugs Market, 2019-2029

  • 9.1 Ophthalmic Drugs - A Changing Market Landscape
  • 9.2 Leading Companies in The Ophthalmic Drugs Market, 2018
    • 9.2.1 Ophthalmic Drugs Market: Leading Companies Forecast 2019-2029
    • 9.2.2 Ophthalmic Drugs: Changing Market Shares by Leading Companies 2019-2029
  • 9.3 Novartis (Alcon)
    • 9.3.1 Novartis: Ophthalmic Drugs Portfolio
    • 9.3.2 Novartis: Sales Forecast 2019-2029
    • 9.3.3 Novartis: Ophthalmic Drugs Development Pipeline
    • 9.3.4 Novartis: Recent Developments
    • 9.3.4.1 Novartis Restructures Following Strategic Review
    • 9.3.4.2 Novartis Licenses Ophthotech's Fovista
  • 9.4 Regeneron
    • 9.4.1 Regeneron: Ophthalmic Drugs Portfolio
    • 9.4.2 Regeneron: Recent Developments
    • 9.4.2.1 Expanding Indications for Eylea
    • 9.4.2.2 Eylea/Zaltrap And the Davis-Smyth Patent Agreements
    • 9.4.3 Regeneron: Sales Forecast 2019-2029
    • 9.4.4 Regeneron: Ophthalmic Drugs Development Pipeline
  • 9.5 Allergan (Actavis)
    • 9.5.1 Allergan: Ophthalmic Drugs Portfolio
    • 9.5.2 Allergan: Recent Developments
    • 9.5.2.1 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
    • 9.5.2.2 How Real Is the Threat of Generic Restasis?
    • 9.5.2.3 Valeant's Attempted Takeover Squashed by Actavis Bid
    • 9.5.3 New acqusitions for healthcare development
    • 9.5.4 Allergan: Sales Forecast 2019-2029
    • 9.5.5 Allergan: Ophthalmic Drugs Development Pipeline
  • 9.6 Roche
    • 9.6.1 Roche: Ophthalmic Drugs Portfolio
    • 9.6.1.1 Lucentis: US Sales Forecast 2019-2029
    • 9.6.2 Roche: Sales Forecast 2019-2029
    • 9.6.3 Roche: Ophthalmic Drugs Development Pipeline
  • 9.7 Valeant
    • 9.7.1 Valeant: Ophthalmic Drugs Portfolio
    • 9.7.2 Valeant: Recent Developments
    • 9.7.2.1 Valeant's Acquisition of Bausch and Lomb Still Driving Its Ophthalmic Portfolio
    • 9.7.3 Valeant: Sales Forecast 2019-2029
    • 9.7.4 Valeant: Ophthalmic Drugs Development Pipeline
    • 9.7.5 Valeant: Difficult End to 2015 as well as 2016 Leads to Uncertainty About Company Future
  • 9.8 Santen
    • 9.8.1 Santen: Ophthalmic Drugs Portfolio
    • 9.8.2 Santen: Recent Developments
    • 9.8.2.1 Santen Acquires Novagali Pharma
    • 9.8.2.2 Santen Acquires Merck's Ophthalmic Drugs Portfolio
    • 9.8.3 Santen: Sales Forecast 2019-2029
    • 9.8.4 Santen: Ophthalmic Drugs Development Pipeline
  • 9.9 Bayer
    • 9.9.1 Bayer: Ophthalmic Drugs Portfolio
    • 9.9.2 Bayer: Sales Forecast 2019-2029
  • 9.10 Pfizer
    • 9.10.1 Pfizer: Ophthalmic Drugs Portfolio
      • 9.10.1.1 Xalatan/Xalacom - Pfizer's Leading Ophthalmic Products
      • 9.10.1.2 Macugen - Valeant/Pfizer
    • 9.10.2 Pfizer: Recent Developments
      • 9.10.2.1 Pfizer Attempts to Acquire AstraZeneca
      • 9.10.2.2 Pfizer Attempts Merger with Allergan
    • 9.10.3 Pfizer: Sales Forecast 2019-2029
    • 9.10.4 Pfizer: Ophthalmic Drugs Development Pipeline
  • 9.11 Senju
    • 9.11.1 Senju: Ophthalmic Drugs Portfolio
    • 9.11.2 Senju: Sales Forecast 2019-2029
    • 9.11.3 Senju: Ophthalmic Drugs Development Pipeline
      • 9.11.3.1 Y 39983 (SNJ 1656)
      • 9.11.3.2 Difluprednate (SJE-2079)

10. Ophthalmic Drugs: Research and Development Pipeline, 2019-2029

  • 10.1 The Ophthalmic Drugs Pipeline: Intensive Development Efforts in Retinal Disorders
  • 10.2 Drugs for Retinal Disorders: Development Pipeline
    • 10.2.1 Will Bevasiranib (RXi Pharmaceuticals) Resume Development?
  • 10.3 Retinal Disorders: Filed or Recently Launched
    • 10.3.1 CompaqSipp (conbercept) - Chengdu Kanghong Pharmaceutical
    • 10.3.2 Lipidil (fenofibrate) - Abbott
    • 10.3.3 Iluvien (fluocinolone) - Alimera Sciences
  • 10.4 Drugs in Phase 3 Development for Retinal Disorders
    • 10.4.1 AGN150998 And MP0260 (Anti-VEGFDARPins) - Allergan
    • 10.4.2 Fovista and Zimura - Ophthotech Corporation
    • 10.4.3 Lampalizumab (anti-FactorD Fab) - Roche
    • 10.4.4 MC-1101 (hydralazine) - Macu CLEAR
    • 10.4.5 Squalamine (anti-angiogenic drug) - OHRPharmaceutical
    • 10.4.6 Tandospirone (serotonin 1A agonist) - Alcon (Novartis)
    • 10.4.7 UF-021 (unoprostone) - R-TechUeno
  • 10.5 Drugs in Phase 2 Development for Retinal Disorders
    • 10.5.1 AKB-9778 (Tie2 activator) - AerpioTherapeutics
    • 10.5.2 Luminate (ALG-1001; Integrin peptide therapy) - Allegro/Senju
    • 10.5.3 AGN208397 (beclomethasone) - Allergan
    • 10.5.4 CPC 551 - ColbyPharmaceutical
    • 10.5.5 ESBA1008 (anti-VEGF mAb) - Alcon (Novartis)
    • 10.5.6 iCo-007 (antisense inhibitor of C-raf kinase mRNA) - iCo Therapeutics
    • 10.5.7 LFG316 (anti-C5 mAb) - Novartis
    • 10.5.8 Intravitreal brimonidine implant - Allergan
    • 10.5.9 Optina (danazol) - Ampio Pharmaceuticals
    • 10.5.10 PF-655 (synthetic siRNA) - Quark/Pfizer
    • 10.5.11 Premiplex (SHP-607) - Shire
    • 10.5.12 Renexus (ciliary neurotrophic factor) - Neurotech
    • 10.5.13 Zybrestat (fosbretabulin) - Oxigene/SymphonyVIDA
  • 10.6 DrugsInPhase 1 and Pre-clinical Developmentfor RetinalDisorders
    • 10.6.1 BDM-E - BioDiem
    • 10.6.2 NADPHOxidaseInhibitors - AlimeraSciences
    • 10.6.3 PAN-90806 (topical VEGF inhibitor) - PanOptica
    • 10.6.4 PlasmaKallikreinInhibitors (KVD001) - KalVista
    • 10.6.5 QLT091001 (synthetic retinoid) - QLT
  • 10.7 Drugs in Phase 3 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
    • 10.7.1 EGP-437 (dexamethasone) - EyeGate Pharmaceuticals
    • 10.7.2 IBI-10090 and IBI-20089 - IconBioscience
    • 10.7.3 KPI-121 (loteprednol etabonate) - Kala
  • 10.8 Drugs in Phase 2 Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
    • 10.8.1 CF101 (adenosine A3 receptor agonist) - Can-Fite BioPharma and OphthaliX
    • 10.8.2 FST-100 (povidone-iodine/dexamethasone) - Shire
    • 10.8.3 NVC-422 (auriclosene) - NovaBay
    • 10.8.4 Sarilumab - Regeneron
  • 10.9 Drugs in Phase 1 And Pre-clinical Development for Allergic, Inflammatory and Infective Ophthalmic Conditions
    • 10.9.1 Finafloxacin - MerLion Pharmaceuticals/Novartis
  • 10.10 Drugs for Glaucoma: Development Pipeline, 2016
  • 10.11 Drugs in Phase 2&3 Development for Glaucoma
    • 10.11.1 Latanoprostene Bunod (VESNEO; BOL 303259-X) - Valeant
    • 10.11.2 AMA0076 (ROCK inhibitor) - Amakem
    • 10.11.3 Rhopressa (AR-13324; ROCK and NET inhibitor) AndRoclatan (PG324; ROCK inhibitor) - Aerie Pharmaceuticals
  • 10.12 Drugs in Phase 1 And Pre-clinical Development for Glaucoma
  • 10.13 Drugs in Phase 3 Development for Dry Eye
    • 10.13.1 EBI-005 (IL-1R antagonist) - Eleven Biotherapeutics
    • 10.13.2 Lifitegrast (integrin antagonist) - Shire
    • 10.13.3 Tavilermide (formerly MIM-D3tyrosine kinase receptor antagonist) - Allergan
    • 10.13.4 SI-614 (modified hyaluronate) - Seikagaku
  • 10.14 Drugs in Phase 2 Development for Dry Eye
    • 10.14.1 ESBA105 (TNF-alpha antibody) - Alcon (Novartis)
    • 10.14.2 Kineret (anakinra: IL-1 receptor antagonist) - Amgen/Sobi
  • 10.15 Other Drugs in the Development Pipeline for Ophthalmic Conditions
    • 10.15.1 Brimonidine For Eye Whitening - Valeant
    • 10.15.2 GS-101 (aganirsen) - GeneSignal
    • 10.15.3 Omidria (phenylephrine/ketorolac) - Omeros

11. Qualitative Analysis of the Ophthalmic Drugs Market, 2019-2029

  • 11.1 Market Factors Influencing Ophthalmic Drugs
  • 11.2 SWOT Analysis of the Global Ophthalmic Drugs Market, 2019-2029
  • 11.3 Strengths
    • 11.3.1 A Healthy R&D Pipeline
    • 11.3.2 Advances in Drug Delivery Technologies
    • 11.3.3 Support for Reimbursement and Payment Approvals
    • 11.3.4 Gene Therapy and RNAi Technology
    • 11.3.5 New Ophthalmic Therapeutic Applications for Drugs
    • 11.3.6 Development of Neuroprotective Anti-Glaucoma Medications
    • 11.3.7 Biomarkers as Tools for Better Diagnosis and Treatment
  • 11.4 Weaknesses
    • 11.4.1 Low Levels of Patient Adherence to Treatment
    • 11.4.2 High Treatment Burden on Patients and Healthcare Providers
    • 11.4.3 Under-Diagnosis and Under-Treatment
  • 11.5 Opportunities
    • 11.5.1 Sustained-Release Ocular Implants
    • 11.5.2 The Impact of a Rapidly Ageing Global Population
    • 11.5.3 Increasing Prevalence of Diabetes and Ocular Disease
    • 11.5.4 Glaucoma and Retinal Disorders Set for Most-Marked Increases in Prevalence
    • 11.5.5 Unmet Clinical Need in Many Disease Areas
    • 11.5.6 Economic Growth in Emerging Market Provide Opportunity for Expansion
  • 11.6 Threats
    • 11.6.1 Intensifying Price Regulation in The Market
    • 11.6.2 Generic Competition - Likely to Cause Erosion of Sales for Market Leading Brands
    • 11.6.3 Rising Cost Of R&D
    • 11.6.4 Biosimilars - A Bigger Threat than Generics?
  • 11.7 Porter's Five Force Analysis of The Global Ophthalmic Drugs Market, 2019-2029
    • 11.7.1 Threat of New Entrants
    • 11.7.2 Rivalry Among Competitors
    • 11.7.3 Power of Suppliers
    • 11.7.4 Threat of Substitutes
    • 11.7.5 Power of Buyers

12. Conclusions

  • 12.1 Overview of Current Market Conditions and Market Forecast, 2019-2029
  • 12.2 Leading Sectors in Ophthalmic Drugs In 2018
  • 12.3 Leading Regions in the Ophthalmic Drugs Market In 2018
  • 12.4 Leading Companies in The Ophthalmic Drugs Market, 2018
  • 12.5 What Does the Future Hold for Ophthalmic Drugs?

Appendices

  • Glossary
  • Associated Reports
  • Visiongain Report Sales Order Form

List of Tables

  • Table 2.1 ICD 10 Classification of Visual Impairment, 2010
  • Table 2.2 Main Classes of the Glaucoma Drugs
  • Table 2.3 Drug Treatments for Age-Related Macular Degeneration, 2017
  • Table 2.4 Drug Treatments for Ocular Allergy
  • Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2017
  • Table 2.6 Drug Treatments for Eye Infections, 2017
  • Table 2.7 Clinical Trial Phases
  • Table 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2018
  • Table 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2019-2029
  • Table 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2018-2023, 2023-2029, 2018-2029
  • Table 3.4 The Global Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Sector, 2018, 2023, 2029
  • Table 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m) and Market Shares (%), 2018
  • Table 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029
  • Table 4.3 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029
  • Table 4.4 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m), AGR (%) and CAGR (%), 2019-2029
  • Table 4.5 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 4.6 Avastin: Ophthalmic Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 4.7 Visudyne: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 4.8 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 4.9 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m) and Market Shares (%), 2018
  • Table 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029
  • Table 5.3 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029
  • Table 5.4 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 5.5 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 5.6 Vigamox: Novartis Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 5.7 TobraDex: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 5.8 Cravit: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 5.9 Acular: Sales Forecast ($m, AGR%, CAGR%), 2018-2029
  • Table 5.10 AzaSite: Akorn Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 5.11 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 6.1 Leading Glaucoma Drugs: Revenues ($m) and Market Shares (%), 2018
  • Table 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029
  • Table 6.3 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029
  • Table 6.4 Lumigan and Ganfort: Sales Forecast ($m, AGR%, CAGR%), 2018-2029
  • Table 6.5 Xalatan/Xalacom: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 6.6 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 6.7 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 6.8 Trusopt: Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 6.9 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 6.10 Azopt: Novartis Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 6.11 Tapros: Santen Sales Forecast ($m, AGR%, CAGR%), 2018-2029
  • Table 6.12 Zioptan: Akorn Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 6.13 Other Glaucoma Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 7.1 Leading Dry Eye Drugs: Revenues ($m) and Market Shares (%), 2018
  • Table 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2019-2029
  • Table 7.3 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2018, 2023, 2029
  • Table 7.4 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 7.5 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 7.6 Hyalein: Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 7.7 Diquas: Santen Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 7.8 Other Dry Eye Drugs: Sales Forecast ($m, AGR%), 2019-2029
  • Table 7.9 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) and Market Share (%) by Region, 2018
  • Table 8.2 Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2019-2029
  • Table 8.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2018-2023, 2023-2029, and 2018-20289
  • Table 8.4 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2018, 2023, and 2029
  • Table 8.5 The US Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.6 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.7 The US Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.8 EU5 Ophthalmic Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2018-2029
  • Table 8.9 EU5 Ophthalmic Drugs Market: Revenue ($m), and Market Share (%) by Country, 2018
  • Table 8.10 EU5 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.11 EU5 Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.12 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2018, 2023, 2029
  • Table 8.13 The German Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.14 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.15 The Germany Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.16 The French Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.17 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.18 France Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.19 The UK Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.20 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.21 UK Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.22 The Italian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.23 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.24 Italy Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.25 The Spanish Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.26 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.27 Spain Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.28 The Japanese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.29 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.30 Japan Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.31 The Chinese Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.32 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.33 China Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.34 The Brazilian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2019-2029
  • Table 8.35 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.36 Brazil Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.37 The Russian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2017-2028
  • Table 8.38 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.39 Russia Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.40 The Indian Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.41 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.42 India Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 8.43 The Rest of the World Ophthalmic Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2018-2029
  • Table 8.44 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 8.45 Row Ophthalmic Drugs Market Forecast by Sector, 2019-2029
  • Table 9.1 Leading Ophthalmic Drug Companies: Revenues ($m) and Market Shares (%), 2018
  • Table 9.2 Ophthalmic Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Leading Companies, 2019-2029
  • Table 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2018, 2023, 2029
  • Table 9.4 Novartis: Company Overview, 2018
  • Table 9.5 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.6 Regeneron: Company Overview, 2018
  • Table 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.8 Allergan: Company Overview, 2018
  • Table 9.9 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.10 Roche: Company Overview, 2018
  • Table 9.11 Lucentis (Roche): US Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.12 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.13 Valeant: Company Overview, 2018
  • Table 9.14 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.15 Santen: Company Overview, 2016
  • Table 9.16 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.17 Bayer: Company Overview, 2018
  • Table 9.18 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.19 Pfizer: Company Overview, 2016
  • Table 9.20 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.21 Senju: Company Overview, 2018
  • Table 9.22 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 9.23 Other Companies: Ophthalmic Drugs Revenue Forecast ($m, AGR%, CAGR%), 2019-2029
  • Table 10.1 Retinal Disorders Drugs Pipeline: Phase 3 Drugs
  • Table 10.2 Retinal Disorders Drugs Pipeline: Phase 2 Drugs
  • Table 10.3 Retinal Disorders Drugs Pipeline: Phase 1 and Pre-clinical Drugs
  • Table 10.4 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 3 Drugs
  • Table 10.5 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 2 Drugs
  • Table 10.6 Allergic, Inflammatory and Infective Drugs Pipeline: Phase 1 and Pre-clinical Drugs
  • Table 10.7 Glaucoma Drugs Pipeline: Phase 2&3 Drugs
  • Table 10.8 GlaucomaDrugsPipeline: Phase 1 and Pre-clinical Drugs
  • Table 10.9 DryEyeDrugsPipeline: Phase 3 Drugs
  • Table 10.10 DryEyeDrugsPipeline: Phase 2 Drugs
  • Table 10.11 OtherPipelineProducts for OphthalmicConditions
  • Table 11.1 SWOT Analysis of the Global Ophthalmic Drugs Market, 2019-2029
  • Table 11.2 World 65+ Population Forecast: Size (m), AGR (%), CAGR (%), 2017-2028
  • Table 11.3 Global Prevalence Forecast for Ophthalmic Diseases
  • Table 12.1 Global Ophthalmic Drugs: Market Forecast ($m, CAGR%), 2018, 2023 and 2029
  • Table 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2018, 2023, 2029
  • Table 12.3 Top ten ophthalmic drug companies in 2018

List of Figures

  • Figure 1.1 Global Ophthalmic Drugs Market: Market Sectors, 2018
  • Figure 2.1 Structure of The Human Eye
  • Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2014
  • Figure 2.3 Global Causes of Visual Impairment (% of cases), 2012
  • Figure 2.4 Classification of Glaucoma, 2016
  • Figure 3.1 The Global Ophthalmic Drugs Market: Revenue ($m) by Sector, 2018
  • Figure 3.2 The Global Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 3.3 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2018-2023
  • Figure 3.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2023-2029
  • Figure 3.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Sector, 2018-2029
  • Figure 3.6 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2018
  • Figure 3.7 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2023
  • Figure 3.8 The Global Ophthalmic Drugs Market: Market Share (%) by Sector, 2029
  • Figure 4.1 Top Drugs in The Retinal Disorder Drugs Market: Revenue ($m), 2018
  • Figure 4.2 Retinal Disorder Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 4.3 Retinal Disorder Drugs Market: Revenue Forecast ($m) by Leading Drugs, 2019-2029
  • Figure 4.4 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2018
  • Figure 4.5 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2023
  • Figure 4.6 The Global Retinal Disorder Drugs Market: Market Share (%) by Leading Drugs, 2029
  • Figure 4.7 Eylea: Regeneron/ Bayer/ Santen Sales Forecast ($m, AGR%), 2019-2029
  • Figure 4.8 Lucentis: Novartis/ Roche Sales Forecast ($m, AGR%), 2019-2029
  • Figure 4.9 Avastin: Ophthalmic Sales Forecast ($m, AGR%), 2019-2029
  • Figure 4.10 Visudyne: Sales Forecast ($m, AGR%), 2018-2029
  • Figure 4.11 Jetrea: ThromboGenics/ Novartis Sales Forecast ($m, AGR%), 2018-2029
  • Figure 4.12 Other Retinal Disorder Drugs: Sales Forecast ($m, AGR%), 2019-2029
  • Figure 5.1 Leading Drugs in The Allergic, Inflammatory and Infective Drugs Market: Revenue ($m), 2018
  • Figure 5.2 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 5.3 Allergic, Inflammatory and Infective Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2019-2029
  • Figure 5.4 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2018
  • Figure 5.5 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2023
  • Figure 5.6 The Global Allergic, Inflammatory and Infective Drugs Market: Market Share (%) by Leading Drugs, 2028
  • Figure 5.7 Pataday: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2018-2029
  • Figure 5.8 Patanol: Novartis/Kyowa Hakko Kirin Sales Forecast ($m, AGR%), 2019-2029
  • Figure 5.9 Vigamox: Novartis Sales Forecast ($m, AGR%), 2019-2029
  • Figure 5.10 TobraDex: Sales Forecast ($m, AGR%), 2019-2029
  • Figure 5.11 Cravit: Sales Forecast ($m, AGR%), 2019-2029
  • Figure 5.12 Acular: Sales Forecast ($m, AGR%), 2018-2029
  • Figure 5.13 AzaSite: Akorn Sales Forecast ($m, AGR%), 2018-2028
  • Figure 5.14 Other Allergic, Inflammatory, And Infective Drugs: Sales Forecast ($m, AGR%), 2019-2029
  • Figure 6.1 Leading Glaucoma Drugs: Revenue ($m), 2018
  • Figure 6.2 Glaucoma Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 6.3 Glaucoma Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2019-2029
  • Figure 6.4 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2018
  • Figure 6.5 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2023
  • Figure 6.6 The Global Glaucoma Drugs Market: Market Share (%) by Leading Drugs, 2029
  • Figure 6.7 Lumigan and Ganfort: Sales Forecast ($m, AGR%), 2018-2029
  • Figure 6.8 Xalatan/Xalacom: Sales Forecast ($m, AGR%), 2019-2029
  • Figure 6.9 Travatan/Travatan Z and DuoTrav: Sales Forecast ($m, AGR%), 2019-2029
  • Figure 6.10 Alphagan/Alphagan P and Combigan: Sales Forecast ($m, AGR%), 2019-2029
  • Figure 6.11 Trusopt: Merck/Santen Sales Forecast ($m, AGR%), 2019-2029
  • Figure 6.12 Cosopt/Cosopt PF: Akorn/Merck/Santen Sales Forecast ($m, AGR%), 2019-2029
  • Figure 6.13 Azopt: Novartis Sales Forecast ($m, AGR%), 2019-2029
  • Figure 6.14 Tapros: Santen Sales Forecast ($m, AGR%), 2018-2029
  • Figure 6.15 Zioptan: Akorn Sales Forecast ($m, AGR%), 2019-2029
  • Figure 6.16 Other Glaucoma Drugs: Sales Forecast ($m, AGR%), 2019-2029
  • Figure 7.1 Leading Dry Eye Drugs: Revenue ($m), 2018
  • Figure 7.2 Dry Eye Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 7.3 Dry Eye Drugs Market: Market Forecast ($m, AGR%) by Leading Drugs, 2019-2029
  • Figure 7.4 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2018
  • Figure 7.5 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2023
  • Figure 7.6 The Global Dry Eye Drugs Market: Market Share (%) by Leading Drugs, 2029
  • Figure 7.7 Restasis: Allergan (Actavis) Sales Forecast ($m, AGR%), 2019-2029
  • Figure 7.8 Refresh Brand: Allergan (Actavis) Sales Forecast ($m, AGR%), 2019-2029
  • Figure 7.9 Hyalein: Santen Sales Forecast ($m, AGR%), 2018-2029
  • Figure 7.10 Diquas: Santen Sales Forecast ($m, AGR%), 2018-2029
  • Figure 7.11 Other Dry Eye Drugs: Sales Forecast ($m, AGR%, CAGR%), 2019-2029
  • Figure 7.12 Hetlioz: Vanda Pharma Sales Forecast ($m, AGR%), 2019-2029
  • Figure 8.1 The Global Ophthalmic Drugs Market: Market Size ($m) by Region, 2018
  • Figure 8.2 US, EU5, China and Japan Ophthalmic Drugs Market: Market Forecast ($m), 2019-2029
  • Figure 8.3 Brazil, Russia and India Ophthalmic Drugs Market: Market Forecast ($m), 2018-2029
  • Figure 8.4 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2018-2023
  • Figure 8.5 The Global Ophthalmic Drugs Market Forecast: CAGR (%) by Region, 2023-2029
  • Figure 8.6 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2018
  • Figure 8.7 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2023
  • Figure 8.8 The Global Ophthalmic Drugs Market Forecast: Market Share (%) by Region, 2029
  • Figure 8.9 US Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.10 US Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.11 EU5 Ophthalmic Drugs Market: Revenue ($m) by Country, 2018
  • Figure 8.12 Germany, France, UK, Italy, and Spain Ophthalmic Drugs Market: Market Forecast ($m), 2019-2029
  • Figure 8.13 EU5 Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.14 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2018
  • Figure 8.15 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2023
  • Figure 8.16 EU5 Ophthalmic Drugs Market: Market Share (%) by Country, 2029
  • Figure 8.17 The German Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.18 Germany Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.19 The French Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.20 France Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.21 The UK Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.22 UK Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.23 The Italian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.24 Italy Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.25 The Spanish Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.26 Spain Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.27 The Japanese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.28 Japan Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.29 The Chinese Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.30 China Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.31 The Brazilian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.32 Brazil Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.33 The Russian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.34 Russia Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.35 The Indian Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.36 India Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 8.37 The Rest of the World Ophthalmic Drugs Market: Market Forecast ($m, AGR%), 2019-2029
  • Figure 8.38 ROW Ophthalmic Drugs Market: Sub- Market Forecast, 2019-2029
  • Figure 9.1 Leading Ophthalmic Drug Companies: Revenue ($m), 2018
  • Figure 9.2 Ophthalmic Drugs Market: Market Forecast ($m) by Leading Companies, 2019-2029
  • Figure 9.3 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2018
  • Figure 9.4 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2023
  • Figure 9.5 The Global Ophthalmic Drugs Market: Market Share (%) by Leading Companies, 2029
  • Figure 9.6 Novartis: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
  • Figure 9.7 Regeneron: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
  • Figure 9.8 Allergan: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 201-2029
  • Figure 9.9 Lucentis (Roche): US Revenue Forecast ($m, AGR%), 2018-2029
  • Figure 9.10 Roche: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
  • Figure 9.11 Valeant: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
  • Figure 9.12 Santen: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
  • Figure 9.13 Bayer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
  • Figure 9.14 Pfizer: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
  • Figure 9.15 Senju: Ophthalmic Drugs Revenue Forecast ($m, AGR%), 2019-2029
  • Figure 11.1 World 65+ Population Forecast: Size (m), AGR (%), 2017-2028
  • Figure 11.2 Global Prevalence of Diabetes and Diabetic Retinopathy, 2010 and 2030
  • Figure 11.3 Porter's Five Force Analysis of the Ophthalmic Drugs Market, 2017
  • Figure 12.1 Global Ophthalmic Drugs: Market Forecast ($m), 2018 - 2029
  • Figure 12.2 The Global Ophthalmic Drugs Market: Market Forecast ($m) by Region, 2018-2029

Companies Listed

  • Abbott
  • AbbVie
  • Actavis
  • Acucela
  • Advanced Cell Technologies
  • Aerie Pharmaceuticals
  • Aerpio Therapeutics
  • Akorn Inc
  • Alcon
  • Alimera Sciences
  • Allegro
  • Allergan
  • Amakem
  • Amgen
  • Ampio Pharmaceuticals
  • Apotex Inc
  • AstraZeneca
  • Aurobindo Pharma Ltd
  • Barr Laboratories Inc.
  • Bausch & Lomb
  • Bayer
  • Bicycle Therapeutics
  • Biocad
  • BioDiem
  • BioXpress Therapeutics
  • Can-Fite BioPharma
  • Chengdu Kanghong Pharmaceutical
  • Chiesi Farmaceutici S.p.A
  • Cipla
  • Colby Pharmaceutical Company
  • Daiichi Sankyo
  • Eleven Biotherapeutics
  • EyeCyte
  • EyeGate Pharmaceuticals
  • ForeSight Biotherapeutics
  • Gene Signal
  • Genentech
  • GSK
  • iCO Therapeutics
  • Icon Bioscience
  • InSite Vision
  • Inspire Pharmaceuticals
  • Instituto Terapeutico Delta Ltda
  • Kala Pharmaceuticals
  • KalVista
  • Kestrel Ophthalmics
  • Kyowa Hakko Kirin
  • LEO Pharma
  • MacuCLEAR
  • Meda
  • Merck & Co.
  • MerLion Pharmaceuticals
  • Morgan Stanley
  • Neurim Pharmaceuticals
  • Neurotech
  • NovaBay
  • Novartis
  • Ohr Pharmaceutical
  • Omeros
  • OphthaliX
  • Ophthotech Corporation
  • Oxigene
  • PanOptica
  • Patheon Pharmaceuticals
  • Pfizer
  • Pharmacia
  • Premacure
  • pSivida
  • QLT
  • Quark Pharmaceuticals
  • Reckitt Benckiser
  • Regeneron
  • Roche
  • R-Tech UENO
  • RXi Pharmaceuticals
  • Santen
  • SARcodeBioscience
  • Seikagaku
  • Senju
  • Servier
  • Shire
  • Sobi
  • Spark Therapeutics
  • SymphonyVIDA
  • Takeda
  • Thrombogenics
  • Upjohn
  • USV North America
  • Valeant
  • Vanda Pharmaceuticals
  • Warner-Lambert
  • Watson
  • Wockhardt
  • Wyeth Pharmaceuticals
  • Zach System Spa

List of Organizations Mentioned in the Report

  • American Academy of Ophthalmology (AAO)
  • American Society of Retina Specialists (ASRS)
  • CDSCO (India)
  • European Union
  • European Commission
  • Health Canada (Canada)
  • Institute of Experimental Medicine
  • Italian Competition Authority (ICA)
  • Italian National Health Service
  • Japanese Ministry of Health, Labour and Welfare (MHLW)
  • MCC (South Africa)
  • MHLW (Japan)
  • MHRA (UK)
  • PAHO
  • SFDA (China)
  • TGA (Australia)
  • University of Modena
  • US National Eye Institute (NEI)
  • World Health Organization (WHO)
  • WIPO
  • WTO
Back to Top